Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects

Authors :: He, Yan-Ling
Ligueros-Saylan, Monica
Sunkara, Gangadhar
Sabo, Ron
Zhao, Charlie
Campestrini, Joelle
Pommier, Francoise
Dole, Kiran
Marion, Alan
Dole, William P.
Howard, Dan
Source :: Journal of Clinical Pharmacology. January 2008, Vol. 48 Issue 1, p85, 11 p.
Publication Year :: 2008
Abstract: Keywords: Dipeptidyl peptidase IV inhibitor; angiotensin converting enzyme inhibitor; angiotensin receptor blocker; calcium channel blocker; pharmacokinetics; type 2 diabetes; vildagliptin 85 Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No [...]

Subjects :: Pharmacokinetics -- Research
Enzyme inhibitors -- Dosage and administration -- Research
Amlodipine -- Dosage and administration -- Research
Health
Research
Dosage and administration

Full Text Access

Tools